Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc. (PMCB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2023 (Event Date)
Reporting Period: Specific event reporting for May 2023 transactions.
The Company announced the closing of a private placement of securities and the commencement of a tender offer for its common stock.
Key Financial Metrics and Transaction Details
Capital Raise (Private Placement):
- Gross Proceeds: Approximately $35 million.
- Securities Issued: 35,000 shares of Series B Convertible Preferred Stock (stated value $1,000/share) and warrants to acquire up to 8,750,000 shares of Common Stock.
- Conversion/Exercise Price: $4.00 per share for both Preferred Stock and Warrants.
- Placement Fee: 6% of gross proceeds paid to Katalyst Securities LLC.
- Use of Proceeds: General corporate purposes.
Tender Offer:
- Target: Up to 7,750,000 shares of Common Stock.
- Consideration: Cash (specific price not disclosed in this filing).
- Status: Commenced May 11, 2023; formal Offer to Purchase to be filed subsequently.
Financial Statements: This filing does not provide revenue, profit, cash flow, or margin data. It is a current report regarding specific corporate actions.
Material Changes and Terms
Preferred Stock Terms:
- Dividends: 4% per annum, compounded monthly (payable in cash or stock). Increases to 15% per annum upon a "Triggering Event."
- Redemption: Mandatory monthly installments commencing November 9, 2023. Payments may be made in cash or stock, subject to pricing limitations and Nasdaq stockholder approval thresholds.
- Forced Conversion: Company may force conversion if Common Stock closes above $6.00 for 20 consecutive trading days with volume exceeding 1,000,000 shares/day.
- Triggering Events: Include failure to file/maintain registration statements or failure to pay amounts due. Triggers allow holders to demand cash redemption at a premium.
Warrant Terms:
- Duration: 5 years from issuance.
- Adjustment: Full ratchet anti-dilution protection if securities are issued below the exercise price.
Registration Rights: Company must file a resale registration statement covering 200% of the Conversion Shares and Warrant Shares within 30 days of the agreement effectiveness.
Outlook, Risks, and Contingencies
- Stockholder Approval: The Company must seek stockholder approval for the issuance of shares exceeding 19.9% of outstanding common stock by October 1, 2023, to fully utilize stock settlement options for redemption and conversion.
- Liquidity Risk: Mandatory monthly redemption payments starting November 2023 could strain liquidity if the Company elects or is required to pay in cash.
- Penalties: Liquidated damages apply if the Company fails to file or maintain the required registration statement for the investors' securities.
- Tender Offer Uncertainty: The tender offer is subject to the terms of the formal Offer to Purchase, which was not yet available at the time of this filing.
Investor Verification Checklist
- Verify the specific cash price per share for the tender offer in the subsequent "Offer to Purchase" document.
- Confirm the Company's current cash position to assess ability to meet mandatory monthly redemption payments starting November 2023.
- Monitor the timeline for the stockholder meeting required by October 1, 2023, to approve share issuances exceeding Nasdaq limits.
- Review the full text of the Certificate of Designations (Exhibit 4.1) for specific definitions of "Triggering Events" and redemption premiums.
- Check for the filing of the resale registration statement (S-1 or S-3) required within 30 days of the May 9 agreement.